Dataset Information


Novel approaches in anaplastic thyroid cancer therapy.

ABSTRACT: Anaplastic thyroid cancer (ATC), accounting for less than 2% of all thyroid cancer, is responsible for the majority of death from all thyroid malignancies and has a median survival of 6 months. The resistance of ATC to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression, contributes to the very poor prognosis of this malignancy. This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways. Lastly, novel approaches and agents involving the Notch1 pathway, nuclear factor ?B, Trk-fused gene, cancer stem-like cells, mitochondrial mutation, and tumor immune microenvironment are discussed. With a better understanding of the biological process and treatment modality, the hope is to improve ATC outcome in the future.


PROVIDER: S-EPMC4221369 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7205985 | BioStudies
2012-01-01 | S-EPMC3480355 | BioStudies
1000-01-01 | S-EPMC6112835 | BioStudies
2020-01-01 | S-EPMC7137046 | BioStudies
2019-01-01 | S-EPMC6944019 | BioStudies
2017-01-01 | S-EPMC5314727 | BioStudies
2019-01-01 | S-EPMC6627963 | BioStudies
1000-01-01 | S-EPMC4653714 | BioStudies
2017-01-01 | S-EPMC5331066 | BioStudies
2014-01-01 | S-EPMC4000830 | BioStudies